anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Dietary factors may be implicated in the formation of kidney stones and should be closely monitored. To achieve this aim, patients are routinely assessed by means of generic dietary recall, a tool widely used by authors in a range of extensive patient populations to record food intake; the findings obtained, however, may be skewed due to dietary variations and underestimation of the effect of food additives. Fifty Frequent Kidney Stone Formers (FKSFs, mean age: 54.3 ± 13.9 years) with normal kidney function, absence of comorbidities, and reliable compliance were selected from a total of 68 patients' resident in Sardinia, an Italian island where genetic admixtures have been relatively rare for generations. The study, conducted from 1 January 2020 to 31 December 2023, was aimed at assessing nutritional values based on the meticulous recording of food quantities, quality, and potential modifications related to food preparation. Patients were selected during an initial clinical check-up and all efforts made to ensure they were capable of reliably recording all food and drinks consumed. A seven-day food diary was provided in which food and drink intake and their impact on 24 h urine output was recorded. The following parameters were measured in both foods and urine output: citrates, oxalates, calcium, phosphorous, uric acid, proteins and nitrogen compounds, magnesium, sulfates, potassium, carbohydrates, free fatty acids. Study outcomes established the presence of hypocitraturia, hyperoxaluria, hypercalciuria, and moderately high levels of nitrogen compounds. Univariate analysis followed by multivariate analysis for further confirmation were performed and the following observations made. Citrate intake correlated with citraturia but did not promote oxaluria; calcium intake promoted onset of sulfaturia, azoturia, and ammoniuria, whilst magnesium correlated with magnesiuria but not with oxaluria, calciuria, phosphaturia, and azoturia; sulfate intake elicited onset of azoturia but not kaliuresis; potassium intake promoted oxaluria and protein intake resulted in onset of ammoniuria and azoturia. (A) The chemical composition of urine based on dietary intake is hard to predict without taking into account the presence of dietary and urinary interferents; (B) the geographic isolation of patients studied underlines the importance of epigenetics in maintaining a traditional dietary heritage. (C) Moreover, the widespread use of food additives should consistently be taken into account to ensure a correct diagnosis of FKSF and set up a valid treatment plan.
On Cycle 1, Day 1 of the Dose Confirmation Phase and during all subsequent cycles, participants with NSCLC receive quavonlimab at DL1 in combination with pembrolizumab at PDL1, both according to Schedule 1. Participants will be treated for up to 35 cycles total on study.
The invention relates to a folic acid cyclodextrin inclusion compound and a preparation method thereof. Comprises folic acid and cyclodextrin or hydroxypropyl-beta-cyclodextrin in a mass ratio of 1: 2-1: 50. Sodium alginate is also added to promote the inclusion of the cyclodextrin to folic acid and improve the redissolution speed of the cyclodextrin inclusion compound after freeze drying. The dosage is 1/4-1/3 based on folic acid. The preparation method comprises the steps of dissolving cyclodextrin and folic acid in a mixed solvent of water and an organic solvent, then placing the mixture in a microwave at 60 ℃ for reaction for 2-3 minutes, filtering, removing free raw materials, and drying in vacuum. The invention utilizes the cyclodextrin inclusion effect to include folic acid to form a stable inclusion compound, and the solubility and the bioavailability of folic acid are increased.
Aim: aimed to compare the effects of High-Velocity Low-Amplitude (HVLA) manipulation and myofascial release techniques on performance in healthy individuals with sacroiliac joint dysfunction. Design: Randomized control trial. Setting: University physiotherapy clinic. Participiants: Participants aged 18-45 years with confirmed Dysfunction by six clinical Sacroiliac Joint diagnostic tests. Intervention: The groups determined as randomly into the four groups. Group I (n=14) received HVLA spinal manipulation, Group II (n=14) underwent foam roller stretching, Group III (n=14) received a combination of HVLA spinal manipulation and foam roller stretching, and Group IV (n=14) underwent sham manipulation as the control group. Measures were measured before the acute intervention and right after the intervention. Outcomes: Prior to the interventions, participants were evaluated using the Visual Analog Scale (VAS) for pain assessment, the Baseline Sit and Reach test for flexibility assessment, the Optojump Next system (Via Stradivari, Bolzano) for vertical jump performance and multiple jump tests, and the MicroFet2 digital hand dynamometer (United States, Utah) for muscle strength measurement. Results: The study groups showed statistically significant improvements in performance parameters compared to the control group (p\<0.05). Pre-treatment and post-treatment performance parameters and pain values were statistically significant in both groups (p\<0.05). While performance improvements were observed in all four groups, the highest changes were generally observed in the HVLA + Myofascial release group. Conclusion: Considering the overall results, the combined use of HVLA and Myofascial release in the treatment protocol is recommended.
The invention discloses a traditional Chinese medicine for treating peritus ani. The traditional Chinese medicine is prepared from the following raw materials: 5-20 parts of fructus cnidii, 5-20 parts of radix sophorae flavescentis, 5-20 parts of golden cypress, 5-20 parts of divaricate saposhnikovia root, 5-20 parts of cortex lycii radicis, 5-20 parts of radix clematidis, 5-20 parts of cortex dictamni, 5-20 parts of Radix Stemonae, 5-20 parts of rhizoma atractylodis, 5-20 parts of purslane, 3-15 parts of folium artemisiae argyi and 3-15 parts of mint. The invention also discloses a method for preparing the traditional Chinese medicine. The traditional Chinese medicine disclosed by the invention has the effects of clearing away heat and drying dampness and killing parasites to relieve itching. The pharmacodynamic test proves that the traditional Chinese medicine has good effects of diminishing inflammation, inhibiting bacteria, relieving itching and resisting allergy and can be used for treating various primary and secondary peritus ani. The clinical symptoms of the peritus ani, particularly peritus ani caused by anal eczema and anorectal operation, can be obviously improved, the clinical cure rate can be over 90 percent, and peritus ani is difficult to reoccur within 5 years.
Subjects will have surgery as their initial breast therapy. If subjects are insufficient (25-hydroxy Vit D 21-29 ng/mL)or deficient (25-hydroxyVit D \<20ng/mL) Vitamin D levels, they will be assigned to this group.
Traditional exercise therapy for knee OA primarily focuses on lower limb strength and joint motion deficits. Recent evidence has suggested that changes in lower limb biomechanical factors during weight bearing activities may have substantial impact on physical function and disease progression in individuals with knee OA. The effectiveness of exercise therapy programs might be improved by incorporating balance and agility training techniques (knee stability training). The aim of this trial is to test the effectiveness of supplementing traditional exercise therapy with knee stability training techniques tailored for individuals with knee OA.

Participants will be randomly assigned to one of two groups. The first group will participate in a standard rehabilitation program of traditional exercise therapy for knee OA. The second group will participate in a standard rehabilitation program supplemented with a knee stability program. Study visits will occur at study entry, 2 months, 6 months, and 1 year. At each study visit, changes in pain, physical function, and biomechanical factors will be assessed. This study will last for one year.
Human α 2 -antiplasmin (α 2 AP) is the major inhibitor of the proteolytic enzyme plasmin that digests fibrin. Two forms of α 2 AP circulate in human plasma: a 464-residue protein, which we have termed “pro”-form, or α 2 AP pro  and an N-terminally-shortened 452-residue “activated”-form, or α 2 AP act . The latter becomes crosslinked to fibrin by activated factor XIII about 5-fold more rapidly than α 2 AP pro  and makes fibrin resistant to digestion by plasmin. A new human plasma proteinase has been identified herein that cleaves the Pro12-Asn13 bond of α 2 AP pro  to yield α 2 AP act . This enzyme is identified herein as Antiplasmin Cleaving Enzyme (APCE).  
     Novel inhibitors of circulating APCE can diminish α 2 AP inhibitory capacity within forming fibrin or blood clots thereby making fibrin deposits or blood clots more susceptible to removal by plasmin. Patients who are susceptible to atherosclerotic plaque formation or are susceptible to developing thrombi that compromise organ function will benefit by therapies providing such inhibitors on a long term basis.
NEW MATERIAL:The compound of formula I [X is H or arenesulfonyl; R is H, acyl or 2-(arenesulfonyl)-1,1-diazanediylalkyliden-1-yl]. EXAMPLE:4-Cyanomethylthioindole. USE:A synthetic raw material for novel indole derivative of formula II [A-B is group of formula III (R<2> is H or lower alkyl or formula IV] having antitumor activity and useful as a synthetic raw material for an antibiotic substance chuanghsinmycin. PREPARATION:A compound of formula I wherein X is arenesulfonyl can be produced by reacting a compound of formula V (X is arenesulfonyl; R<2> is lower alkyl) with chloroacetonitrile or bromoacetonitrile in the presence of ethylenediamine. The product can be easily converted to another compound of formula I wherein X is H by the detosylation reaction e.g. with Na salt of cyclohexanol.
The present invention discloses a medicinal composition and a preparation method thereof. The medicinal composition is prepared from taurine, hyodeeoxycholic acid, baicalin, gardenia and nacre. The preparation method comprises the following steps: firstly, gardenia extracting liquid and nacre powder hydrolyzing liquid are prepared, and then, hyodeeoxycholic acid powder and taurine powder are added to regulate the pH value to obtain mixed medicinal liquid; after the mixed medicinal liquid is deposited by alcohol, fine baicalin powder is added, and the processes of pH value regulation, etc. are carried out to obtain total mixed medicinal liquid; subsequently, the total mixed medicinal liquid is prepared into various preparations. In the present invention, the gardenia extracting processes are improved, and a semi-finished product with geniposide as a main component is formed. The original adverse reactions are basically eliminated under the condition of keeping the biological effect of Qingkailing injections on the treatment of cerebral embolism diseases, and the purposes of stabilizing effect and relieving toxicity are achieved. The medicinal composition and the method of the present invention can be used for the development of new medicine for treating diseases of cerebral embolism and cerebral hemorrhage.
We are conducting a randomized trial to evaluate the comparative effectiveness of a congregation-based Healthy Beginning Initiative (HBI) delivered by lay health advisors (Intervention Group; IG), versus a Facility Based Approach (Control Group; CG) on the HIV testing rate and PMTCT completion among 2,700 pregnant women. Four dioceses with forty churches nested in the dioceses, will be randomly assigned to either the IG (N=2; n=20) or the CG (N=2; n=20). The HBI combines a family educational game show and an integrated on-site laboratory testing in the context of a baby shower. Monthly prayer sessions for pregnant women will be used for recruitment and a baby reception following infant baptisms will be used for follow up after delivery. The primary outcome is difference in testing rate among pregnant women in IG compared to CG. The secondary outcomes are HIV testing rate among male partners and PMTCT completion among HIV-infected pregnant women. Pregnant women will complete an investigator-administered questionnaire at the baby reception to collect information on HIV testing and PMTCT completion. Data will be confirmed with Health Facilities and on-site testing data. This proposal is a collaboration among Partners for Prevention, education, Training, Treatment and Research (PeTR-Global Solutions)/AIDSRelief (our PEPFAR-funded partner in Nigeria responsible for training, HIV testing, linkage to treatment and local oversight of the project); New York University School of Medicine (program evaluation and shares oversight with PI), Board of Regents, NSHE, obo University of Nevada, Reno (provide overall oversight, data management and evaluation of program effectiveness).
BACKGROUND: Bone denudation after conventional relaxing incisions could be a critical factor in inhibiting maxillofacial growth. To address this, alternative relaxing incisions were designed. Thus, this study aimed to compare the effectiveness of palatal relaxing incisions versus nasopharyngeal relaxing incisions in enhancing postoperative outcomes.
MATERIALS AND METHODS: A retrospective cohort study was conducted, involving a total of 120 patients divided into three groups: 40 patients have received modified Furlow palatoplasty with nasopharyngeal relaxing incisions (M.F + N.P.I palatoplasty), and 40 patients who received modified Furlow palatoplasty with palatal relaxing incisions (M.F + P.R.I palatoplasty). The other 40 patients received original Furlow palatoplasty without relaxing incisions (F palatoplasty). Data collected included gender, cleft type, cleft width, age at repair, velopharyngeal function, presence of palatal fistula, and follow-up. The chi-square test compared frequencies of sex, cleft type, postoperative fistula, and velopharyngeal outcomes across groups. The Mann-Whitney and independent t-tests compared mean values, with statistical significance set at p < 0.05.
RESULTS: The mean age at repair was similar across groups, with follow-up periods ranging from 5 to 11 years. No significant differences were found among the M.F + N.P.I and M.F + P.L.I groups regarding gender, cleft type, cleft width, and age at repair. However, the F group had a significantly narrowest cleft width compared to the other groups. Postoperative outcomes showed no significant differences in velopharyngeal function among the three groups, but the F group had a significantly higher rate of palatal fistula (32.5%) compared to the M.F + P.L.I (10%) and M.F + N.P.I (7.5%) groups. A comparison of the two modified Furlow techniques revealed no significant differences in velopharyngeal closure rates or the incidence of velopharyngeal insufficiency and persistent palatal fistula across different Veau classifications.
CONCLUSIONS: While both incisions showed similar impacts on palatoplasty outcomes, palatal relaxing incisions may expose more bone and pose a higher risk of secondary healing issues. Therefore, nasopharyngeal relaxing incisions are recommended as an effective and potentially preferable technique in palatoplasty whenever feasible.
CLINICAL RELEVANCE: The current study suggests that, whenever feasible, nasopharyngeal relaxing incisions are advised as an effective and potentially superior technique in palatoplasty.
Placebo contains all of the excipients except for the active ingredient, caffeine citrate, (a volume equivalent to 10 mg/kg of caffeine citrate) and given daily. Infants will be continued at home on the same dose of placebo for the first 28 days after hospital discharge.
The invention provides compounds and salts of Formula (I) and Formula (II): which possess antimicrobial activity. The invention also provides novel synthetic intermediates useful in making compounds of Formula (I) and Formula (II). The variables A1, R2, R3, R5, R6, R7, A8 and R9 are defined herein. Certain compounds of Formula (I) and Formula (II) disclosed herein are potent and selective inhibitors of bacterial DNA synthesis and bacterial replication. The invention also provides antimicrobial compositions, including pharmaceutical compositions, containing one or more compounds of Formula (I) or Formula (II) and one or more carriers, excipients, or diluents. Such compositions may contain a compound of Formula (I) or Formula (II) as the only active agent or may contain a combination of a compound of Formula (I) or Formula (II) and one or more other active agents. The invention also provides methods for treating microbial infections in animals.
Transcription factors within microglia contribute to the inflammatory response following intracerebral hemorrhage (ICH). Therefore, we employed bioinformatics screening to identify the potential transcription factor tonicity-responsive enhancer-binding protein (TonEBP) within microglia. Inflammatory stimuli can provoke an elevated expression of TonEBP in microglia. Nevertheless, the expression and function of microglial TonEBP in ICH-induced neuroinflammation remain ambiguous. In our recent research, we discovered that ICH instigated an increased TonEBP in microglia in both human and mouse peri-hematoma brain tissues. Furthermore, our results indicated that TonEBP knockdown mitigates lipopolysaccharide (LPS)-induced inflammation and the activation of NF-κB signaling in microglia. In order to more deeply comprehend the underlying molecular mechanisms of how TonEBP modulates the inflammatory response, we sequenced the transcriptomes of TonEBP-deficient cells and sought potential downstream target genes of TonEBP, such as Pellino-1 (PELI1). PELI has been previously reported to mediate nuclear factor-κB (NF-κB) signaling. Through the utilization of CUT & RUN, a dual-luciferase reporter, and qPCR, we confirmed that TonEBP is the transcription factor of Peli1, binding to the Peli1 promoter. In summary, TonEBP may enhance the LPS-induced inflammation and activation of NF-κB signaling via PELI1.
The invention discloses a Chinese medicinal preparation for treating facioplegia. The preparation is prepared from the following raw medicaments: 8 to 12 g of scorpion, 8 to 12 g of centipede, 10 to 15 g of earthworm, 10 to 15 g of Szechuan lovage rhizome, 8 to 12 g of Chinese angelica, 8 to 12 g of peach seeds, 8 to 12 g of safflower, 7 to 12 g of licorice, and 8 to 12 g of red peony root. A preparation method comprises the following steps of: mixing the raw medicaments, adding 1000 milliliters of water, soaking for 1 to 2 hours, decocting to 500 milliliters, and thus obtaining the preparation. The Chinese medicinal preparation has the effects of promoting blood circulation to remove blood stasis and clearing and activating the channels and collaterals; and the pharmacological and pharmacodynamic analysis is as follows: the peach seeds and the safflower have the effect of promoting blood circulation to remove blood stasis; the Chinese angelica, the red peony root and the Szechuan lovage rhizome have the effects of nourishing blood and promoting circulation of blood; and the scorpion, the centipede and the earthworm reach the channels and collaterals and have the effect of removing wind and activating collaterals together. The preparation is mainly used for treating the facioplegia and orally taken during treatment, 250 milliliters of the preparation is taken at night in the first day, and 250 milliliters is taken again in the next morning. Generally, the effect is achieved after the preparation is taken for 6 days, and the disease is healed in 12 days.
The purpose of this study is to determine whether oral fluoxetine can induce lysosomal stress and enhance Temozolomide (TMZ)-induced cell death in patients diagnosed with recurrent malignant glioma. The primary objective is to determine if fluoxetine increases lysosomal stress in patients with recurrent IDHwt glioma by evaluating LAMP1 expression in tumor samples obtained pre-resection via biopsy and during surgery. Following consent, an optional biopsy may be performed to confirm recurrence of high-grade glioma. Recurrent glioma patients for whom retreatment with TMZ is appropriate and who are able to undergo tumor resection after 1 cycle of temozolomide will be enrolled in this study. Following enrollment, patients will randomly be assigned to (1:2) a study arm: control (n=10) or experimental (n=20). Within the experimental arm, two maintenance dose levels of fluoxetine are planned - 40mg OD (n=10) and 60mg OD (n=10). Patients randomized to the control arm will receive only 50 mg/m2 TMZ daily for 7 days (Days 6-12), followed by resection 21 days after initiation of the TMZ cycle. Patients randomized to the experimental arm will receive fluoxetine at 20 mg/day for 5 days (loading initiation dose) followed by a maintenance dose of 40 mg/day starting on Day 6 (dose level 1) or 60 mg/day starting on Day 6 (dose level 2) This truncated initiation period of fluoxetine has been discussed with the psychiatry department at Duke University Hospital and has been judged to be safe given the additional monitoring precautions that are being included as part of this study. On Day 6, patients will start treatment with 50 mg/m2 TMZ daily for 7 days (Days 6-12). Resection will occur 21 days after initiation of the TMZ cycle on Day 27. Patients will remain on their assigned dose of fluoxetine through resection and follow-up, as long as the treatment regimen is tolerated. The change between baseline and post-resection will be computed to determine if co-administration of fluoxetine and TMZ will result in increased expression of LAMP1 on resected glioma cells. Within each group, a Wilcoxon signed-rank test will be conducted to determine if there are significant within group changes. A Kruskal-Wallis test will compare the three patient groups (Control Group, Fluoxetine Group \[low-dose\], Fluoxetine Group \[high-dose\]) with respect to these changes. If data suggests that parametric method are appropriate, then analysis of variance and a paired t-test will be conducted. Risks commonly associated with fluoxetine include nausea, diarrhea, lack of appetite, dry mouth, upset stomach or heartburn, constipation, insomnia, anxiety, nervousness, drowsiness, tremor, unusual dreams, headaches, dizziness, yawning, swelling of face, low body temperature, sexual dysfunction, rash, hives and itching, sweating, flu-like symptoms, sore throat, stuffy nose, and fever.
Study participants will receive pre-defined doses of rozanolixizumab. Each treatment cycle in each Treatment Period (TP) consists of 6 subcutaneous (sc) administrations of rozanolixizumab at 1-week intervals. Each Treatment Period will be initiated upon the discretion of the Investigator based on the medical needs of the study-participant.
Participants randomized to receive placebo will be started on normal saline. In similar fashion to the active comparator, participants will be titrated to their maximal tolerated dose, continue treatment for 48 ± 6 hours, and be weaned at the discretion of the blinded treating physician.
A composition and method for converting alcohol to acetaldehyde and/or acetate and treat alcohol intoxication. The composition can include a therapeutically effective amount of an enzyme and a therapeutically effective amount of a co-factor. The enzymes can be alcohol dehydrogenase (ADH), a derivative of alcohol dehydrogenase, an analog of alcohol dehydrogenase or alcohol dehydrogenase in yeast crude extract. A second enzyme can be aldehyde dehydrogenase (ALDH), a derivative of aldehyde dehydrogenase, an analog of aldehyde dehydrogenase, mitochondrial aldehyde dehydrogenase (ALDH2), a derivative of mitochondrial aldehyde dehydrogenase, an analog of mitochondrial aldehyde dehydrogenase or aldehyde dehydrogenase in yeast crude extract. A co-factor can be utilized in the composition that increases a concentration of Nicotinamide Adenine Dinucleotide (NAD) or Nicotinamide Adenine Dinucleotide Phosphate (NADP). A sugar such as, but not limited to, fructose and a third enzyme sorbitol dehydrogenase (SDH) can be included in the composition.